Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome

[1] Gandhi M(2020)Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19 N Engl J Med 382 2158-2160

[2] Yokoe DS(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 395 1054-1062

[3] Havlir DV(2020)Estimating the burden of SARS-CoV-2 in France Science 10 208-211

[4] Zhou F(2020)Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 130 2620-2629

[5] Yu T(2020)Hlh Across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 1033-1034

[6] Du R(2020)The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China Clinl Immunol 214 108393-724

[7] Fan G(2020)Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients Science 369 718-1635

[8] Liu Y(2020)A dynamic COVID-19 immune signature includes associations with poor prognosis Nat Med 26 1623-1769

[9] Liu Z(2020)Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia J Infect Dis 221 1762-535

[10] Xiang J(2020)Functional exhaustion of antiviral lymphocytes in COVID-19 patients Cell Mol Immunol 17 533-539

[1] Gandhi M(2020)Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19 N Engl J Med 382 2158-2160

[2] Yokoe DS(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 395 1054-1062

[3] Havlir DV(2020)Estimating the burden of SARS-CoV-2 in France Science 10 208-211

[4] Zhou F(2020)Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 130 2620-2629

[5] Yu T(2020)Hlh Across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 1033-1034

[6] Du R(2020)The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China Clinl Immunol 214 108393-724

[7] Fan G(2020)Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients Science 369 718-1635

[8] Liu Y(2020)A dynamic COVID-19 immune signature includes associations with poor prognosis Nat Med 26 1623-1769

[9] Liu Z(2020)Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia J Infect Dis 221 1762-535

[10] Xiang J(2020)Functional exhaustion of antiviral lymphocytes in COVID-19 patients Cell Mol Immunol 17 533-539